VEGFA and cardiovascular disorder: Ye et al. engineered phase-transition MNAs loaded with adeno-associated virus (AAV) to deliver genes of vascular endothelial growth factor (VEGF) for cardiovascular disorder treatment (Figure 2B) 55.